Stein Discusses Unmet Needs and Recommendations for Oncologists Treating AML

Eytan M. Stein, MD, chief of the leukemia service and director for the program for drug development in leukemia at Memorial Sloan Kettering Cancer Center, provides community oncologists with an overview of the unmet needs in the acute myeloid leukemia (AML) space and provides recommendations for those treating patients with this disease.

The AML treatment landscape has seen many positive developments over the last decade, including multiple new approvals, treatments that can be tailored to individual patients, and the addition of Menin inhibitors.

Still, Stein notes that there are a lot more unmet needs that must be addressed in this space as patients still have a poor quality-of-life and end up dying from their disease. He is hopeful that more clinical trials and new agents will continue to make headway in this space.

Transcription:

0:08 | Unfortunately, all of AML is an unmet need. Despite the fact that we've had a number of different drug approvals and patients are living longer and having a better quality of life than they did 10 years ago, most patients will still end up dying of acute myeloid leukemia. A lot of patients still are not cured. Therefore, we need to make these trials and develop therapies that improve patients' survival even longer, and that's what we're trying to do. That's what is happening with Menin inhibitors, and hopefully there are going to be other drugs coming down the pipeline.

0:47 | The key takeaways are that Menin inhibitors are exciting. I think they are going to be the next drugs that are approved for the treatment of a certain subset of acute myeloid leukemia and perhaps acute lymphoblastic leukemia. If you have a patient with an MLL rearrangement or an NTP1 mutation that is relapsed or refractory, go to ClinicalTrials.gov, look up Menin inhibitors, and look for the closest clinical trial in New York to your location.